Skip to content

Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.

Detection Rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Male Genitourinary System and Its Impact on Male Reproductive Health: an Observational Clinical Study.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04388631
Acronym
COVID-19
Enrollment
200
Registered
2020-05-14
Start date
2020-05-10
Completion date
2021-05-01
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus Disease 2019

Keywords

Coronavirus Disease 2019, Male reproductive health, Mental health

Brief summary

This study will evaluate the changes in sexual function, reproductive function and mental health of male patients discharged from the hospital with COVID-19, and the impact of SARS-CoV-2 on male reproductive health and mental health compared with healthy people during the same period. In addition, men's semen examination reports before and after the new coronavirus pneumonia event will be collected and compared to assess the impact of the event on the quality of men's semen. Also, This study will test the SARS-CoV-2 nucleic acid of the urogenital system of male patients discharged with COVID-19 to provide evidence for the effect of the new coronavirus on the male reproductive system.

Detailed description

This study will test SARS-CoV-2 nucleic acids in urine, prostate fluid, and semen of participants with COVID-19 at the first follow-up. All participants will be followed up for 1 year. During follow-up, International Index of Erectile Function-5 (IIEF-5), Quality Evaluation Questionnaire (QEQ), symptom list chart-90 (SCL-90) questionnaire evaluation and sexual function related examinations (including nocturnal penile tumescence, color duplex ultrasonography, etc. ) and fertility-related examinations (including sex hormones, semen routine examinations, etc.) will be performed to assess the changes in male sexual function, reproductive function and mental health of male patients discharged with COVID-19, and the impact of SARS-CoV-2 on male reproductive and mental health. In addition, collect male semen examination reports from April to December in 2017-2020 to evaluate the impact of new coronavirus pneumonia incidents on male semen quality.

Interventions

OTHERCoronavirus Disease 2019

male patients who have developed COVID-19

Sponsors

Tongji Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age≥ 18, ≤ 60 years old; 2. Have a fixed sex partner and regular sex life; 3. No previous infectious diseases, chronic diseases, tumor history, and male sexual function and fertility diseases; 4. Normal erectile function, IIEF-5 score\> 21 points; 5. Have complete clinical information and contact information; 6. Understand and sign the informed consent form.

Exclusion criteria

1. Hypertension, diabetes, coronary heart disease, hyperlipidemia and other chronic diseases; 2. Past history of endocrine diseases such as hypopituitarism, hypogonadism, abnormal thyroid function, etc; 3. Past history of mumps virus infection; 4. Past history of bladder cancer, prostate cancer, brain spine injury, testicular injury, pelvic fracture, urethral injury and history of surgical treatment; 5. Severe cardiovascular and cerebrovascular diseases, severe lung diseases, severe hepatitis; 6. Past psychological or mental illness; 7. Contact information not available.

Design outcomes

Primary

MeasureTime frameDescription
Detection rate of SARS-CoV-2 in male genitourinary system1 monthDetection rate of SARS-CoV-2 in male genitourinary system will be evaluated by real time-polymerase chain reaction (RT-PCR).
Erection hardness and duration3 monthsErection hardness and duration will be evaluated during sleep by RigiscanHealth Organization (WHO) normal values based on the WHO 2010 reference limits.
Sperm density3 monthsSperm density will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.
Sperm activity3 monthsSperm activity will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.
IIEF-5/QEQ questionnaire score3 monthsIIEF-5/QEQ questionnaire score will be obtained by filling out the questionnaire every visit.

Secondary

MeasureTime frameDescription
SCL-90 questionnaire score3 monthsSCL-90 questionnaire score will be obtained using SCL-90 questionnaire.
Semen volume3 monthsSperm volume will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.
Sperm survival rate3 monthsSperm survival rate will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.
Serum testosterone/luteinizing hormone (LH)/follicle stimulating hormone (FSH) level3 monthsThe serum testosterone/LH/FSH levels will be tested in every visit.

Other

MeasureTime frameDescription
Weight3 monthsWeight will be measured at every visit
Clinical classification of COVID-191 monthClinical classification of COVID-19 will be determined according to the New Coronavirus Pneumonia Prevention and Control Program (7th edition) published by the National Health Commission of China
Height3 monthsHeight will be measured at every visit

Countries

China

Contacts

Primary ContactTao Wang, M.D
tjhwt@126.com027-83663640

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026